Evofem Biosciences, Inc. (EVFM): Price and Financial Metrics
EVFM Price/Volume Stats
Current price | $0.01 | 52-week high | $0.23 |
Prev. close | $0.01 | 52-week low | $0.01 |
Day low | $0.01 | Volume | 1,268,300 |
Day high | $0.01 | Avg. volume | 962,959 |
50-day MA | $0.01 | Dividend yield | N/A |
200-day MA | $0.02 | Market Cap | 1.41M |
EVFM Stock Price Chart Interactive Chart >
Evofem Biosciences, Inc. (EVFM) Company Bio
Evofem Biosciences, formerly Neothetics, develops and anticipates commercializing innovative products to address unmet needs in women's sexual and reproductive health. Its lead candidate is Amphora, a non-hormonal, surfactant-free bioadhesive vaginal gel designed for on-demand use as needed or desired by a woman. This investigational new drug is being developed as an on-demand, non-hormonal vaginal contraceptive and for the prevention of certain sexually transmitted infections (STIs). Data from a confirmatory Phase 3 clinical trial of Amphora for the prevention of pregnancy are expected in late 2018/early 2019. A Phase 2b/3 clinical trial of Amphora for the prevention of urogenital chlamydia and gonorrhea in women is also underway. Amphora received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the prevention of urogenital chlamydia in women, and is designated as a Qualified Infectious Disease Product (QIDP) by the U.S. Food & Drug Administration for the prevention of urogenital gonorrhea infection in women. The Company's second multipurpose prevention technology (MPT) vaginal gel candidate has QIDP designation for the reduction of reoccurrence of bacterial vaginosis. These designations may enable Evofem Biosciences to more rapidly evaluate and make these drugs available to women at risk of these infections.
EVFM Price Returns
1-mo | N/A |
3-mo | N/A |
6-mo | N/A |
1-year | N/A |
3-year | N/A |
5-year | N/A |
YTD | N/A |
2023 | N/A |
2022 | N/A |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...